Skip to main content
profile image
Selected Works of Philip Mease, MD
Article
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
The Journal of Rheumatology (2017)
  • Désirée van der Heijde, Leiden University Medical Center
  • Dafna D. Gladman, University of Toronto
  • Mitsumasa Kishimoto, International University, Cambodia
  • Masato Okada, Eli Lilly and Company
  • Suchitrita S. Rathmann, Ghent University Hospital
  • Susan R. Moriarty
  • Catherine L. Shuler, University of Washington
  • Hilde Carlier
  • Olivier Benichou, Eli Lilly and Company
  • Philip J. Mease, University of Washington
Link
Disciplines
Publication Date
December 15, 2017
DOI
10.3899/jrheum.170429
Citation Information
Désirée van der Heijde, Dafna D. Gladman, Mitsumasa Kishimoto, Masato Okada, et al.. "Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)" The Journal of Rheumatology Vol. 45 Iss. 3 (2017) p. 367 - 377
Available at: http://works.bepress.com/philip-mease/23/